Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- history of drug exposure
- skin lesions
- variable skin reactions within 5 to 15 minutes of drug exposure
- variable skin reactions within a few hours of drug exposure
- variable skin reactions within 2 weeks of drug exposure
- variable skin reactions within months to years of drug exposure
- previous exposure and reaction to drug
Outros fatores diagnósticos
- pruritus
- associated noncutaneous features
- pain
Fatores de risco
- virus infections
- HIV infection
- HLA-B*5701 polymorphism
- HLA-B*1502 polymorphism
- HLA-B*5801 polymorphism
- female sex
Investigações diagnósticas
Tests to avoid
- immunoglobulin G (IgG) allergy testing
Investigações a serem consideradas
- blood (whole blood, plasma, serum) drug concentration
- serum tryptase concentration (anaphylaxis)
- complement pathway assay
- histology of lesion biopsy
- CBC and differential
- antihistone antibodies to single-stranded DNA (lupus-like syndrome)
- skin tests (prick tests, intradermal tests, patch tests)
- drug-specific IgE
Novos exames
- basophil activation test
- lymphocyte proliferation assay (LPA/LTT)
- enzyme-linked immunospot assay (ELISPOT test)
Algoritmo de tratamento
serious cutaneous adverse reactions
nonserious cutaneous adverse reactions
following acute episode
Colaboradores
Autores
Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP
Associate Professor
Consultant Dermatologist
Faculty of Medicine
University of Southampton
Southampton
UK
Declarações
MA-J declares that he has no competing interests.
Agradecimentos
Dr Michael Ardern-Jones would like to gratefully acknowledge Dr Wei Yann Haw, Dr Anne Holbrook, Dr Hermenio Lima, and Dr Jeffrey K. Aronson, the previous contributors to this topic.
Declarações
WYH, AH and HL declare that they have no competing interests. JKA is editor of Meyler's Side Effects of Drugs and its annual companion volumes, the Side Effects of Drugs Annuals.
Revisores
Shahbaz A. Janjua, MD
Specialist Dermatologist
Ayza Skin & Research Center
Lalamusa
Pakistan
Declarações
SAJ declares that he has no competing interests.
Craig K. Svensson, Pharm.D, PhD
Dean
College of Pharmacy, Nursing, and Health Sciences
Purdue University
West Lafayette
IN
Divulgaciones
CKS declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. Resumen
Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.
Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(2):3358-63. Resumen
Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972 Dec;27(5):407-38. Resumen
Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70. Resumen
Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022 Dec;150(6):1333-93.Texto completo Resumen
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. Resumen
Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965 Jan;58(1):295-300.Texto completo Resumen
Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009 May;102(5):186-94.Texto completo Resumen
National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014 [internet publication].Texto completo
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Differentials
- Systemic lupus erythematosus
- Autoimmune blistering disorders
- Staphylococcal scalded skin syndrome
Más DiferencialesGuidelines
- Anaphylaxis: a 2023 practice parameter update
- Drug allergy: a 2022 practice parameter
Más GuidelinesLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer